Anthem, the second-biggest health insurer in the US, is partnering with doc.ai and Harvard Medical School researchers on a 12-month innovative study which aims to determine the impact of AI on disease treatment and personalised healthcare. In a statement, Anthem and doc.ai acknowledged "data trials that rely on the confluence of blockchain, precision medicine, and artificial intelligence are a fairly new concept". The partnership will see doc.ai's platform use machine learning algorithms to analyze patient data, including anonymized medical records from across multiple healthcare providers as well as clinical trial data.
Anthem, the second-biggest health insurer in the US, is partnering with doc.ai and Harvard Medical School researchers on a 12-month innovative study which aims to determine the impact of AI on disease treatment and personalised healthcare. In a statement, Anthem and doc.ai acknowledged "data trials that rely on the confluence of blockchain, precision medicine, and artificial intelligence are a fairly new concept". A report by Accenture estimates healthcare's AI market will be worth more than $6bn by 2021.